Table of Content

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Chronic Diseases
4.2.2 Technological Advancements
4.2.3 Growth in the Biologics Market
4.3 Market Restraints
4.3.1 Risk of Needlestick Injuries
4.4 Industry Attractiveness - Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Buyers/Consumers
4.4.2 Bargaining Power of Suppliers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Route of Administration
5.1.1 Injectable
5.1.2 Topical
5.1.3 Ocular
5.1.4 Other Route of Administration
5.2 By Application
5.2.1 Cancer
5.2.2 Cardiovascular
5.2.3 Diabetes
5.2.4 Infectious diseases
5.2.5 Other Applications
5.3 By End User
5.3.1 Hospitals
5.3.2 Ambulatory Surgical Centers
5.3.3 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pfizer Inc.
6.1.2 Novartis AG
6.1.3 F Hoffmann-La Roche Ltd
6.1.4 Johnson and Johnson
6.1.5 Bayer AG
6.1.6 Becton, Dickinson and Company
6.1.7 Altaris
6.1.8 Holozymes Inc. (Antares Pharma Inc.)
6.1.9 GlaxoSmithKline PLC
6.1.10 Teva Pharmaceutical Industries Ltd
6.1.11 Biocorp
6.1.12 Merck KGaA
6.1.13 West Pharmaceutical Services Inc.
6.1.14 Molex (Philips Medisize)
6.1.15 Elcam Medical


7 MARKET OPPORTUNITIES AND FUTURE TRENDS